Results 251 to 260 of about 1,552,446 (340)
Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry
ACR Open Rheumatology, Volume 8, Issue 5, May 2026.Objective
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) such as semaglutide (SEM) and tirzepatide (TZP) were initially approved for type 2 diabetes management but are increasingly used for weight loss. Limited data exist on real‐world use among patients with rheumatic and musculoskeletal diseases (RMDs).Nicholas P. McCormick, Cristiano S. Moura, Jingyi Zhang, Emily E. Holladay, Fenglong Xie, Tapan Mehta, Joshua F. Baker, Jeffrey R. Curtis +7 morewiley +1 more sourceDecoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy‐Induced Cardiac Fibrosis Based on Single‐Cell Transcriptomic Analysis
Advanced Science, Volume 13, Issue 25, 4 May 2026.This study highlights that radioimmunotherapy drives crosstalk between fibroblasts and immune cells (especially macrophages) in the cardiac microenvironment, with IL‐6 as the key mediator, and tocilizumab alleviates cardiac fibrosis by targeting this interplay.Yuxi Luo, Ying Yu, Zhimin Zeng, Yanxin Chen, Yali Yi, Zhiqin Lu, Fujuan Zeng, Peng Xu, Daya Luo, Leifeng Chen, Anwen Liu +10 morewiley +1 more sourceNoonan Syndrome Spectrum Disorders Predispose to Systemic Lupus Erythematosus: Case Report and Critical Review of the Literature
American Journal of Medical Genetics Part A, Volume 200, Issue 5, Page 1091-1097, May 2026.ABSTRACT
RASopathies are clinically overlapping neurodevelopmental syndromes resulting from germline mutations in genes involved in the rat sarcoma/mitogen‐activated protein kinases (RAS/MAPK) pathway. Historically, RASopathies have been described by clinical phenotypes, such as Noonan syndrome and Neurofibromatosis type I.Anastasia‐Vasiliki Madenidou, Gillian I. Rice, James O'Sullivan, Ben Parker, Ian N. Bruce, Emma Burkitt‐Wright, Tracy A. Briggs +6 morewiley +1 more sourceRisk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab
Arthritis &Rheumatology, Volume 78, Issue 5, Page 1134-1144, May 2026.Objective
The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods
This is a post hoc analysis of the RITAZAREM clinical trial.Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators, Reem Al‐jayyousi, Yoshihiro Arimura, Jacqueline Andrews, Simon Bond, Marianna Nodale, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Michael Clarkson, Janak de Zoysa, Vimal Derebail, Tim Doulton, Tomomi Endo, Eri Muso, Tatsuo Tsukamoto, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz‐Singer, Yoshitomo Hamano, Lorraine Harper, Toshiko Ito‐Ihara, Rachel B. Jones, Nader Khalidi, Rainer Klocke, Curry L. Koening, Yoshinori Komagata, Hajime Kono, Shunya Uchida, Carol A. Langford, Peter Lanyon, Sarah Lawman, Raashid Luqmani, Larry W. Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Ken‐ei Sada, Richard Smith, Richard Watts, Robert Spiera, Antoine G. Sreih, Kazuo Suzuki, Vladamir Tesar, Augusto Vaglio, Giles Walters, Caroline Wroe +62 morewiley +1 more sourceSystemic vasculitis.
Indian journal of dermatology, 1987 D C, Kumawat, G N, Saxena, B S, Bomb, A K, Khare, L R, Agarwal, D R, Shah +5 moreopenaire +1 more sourceChronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches
Brain and Behavior, Volume 16, Issue 5, May 2026.Chronic inflammatory demyelinating polyneuropathy is an autoimmune disorder causing demyelination, leading to distal weakness, sensory loss, and autonomic dysfunction. Immune activation triggers macrophage‐mediated myelin damage and conduction failure.Ayesha Khan, Arsal Khan, Kuldeep Dalpat Rai, Anzel Saeed, Harsh Kumar, Aneesh Kumar Sangtiani, Tehreem Fatima, Muhammad Tanveer Alam, Faiza Rajput, Sakshi Chawla, Hussain Haider Shah, Humaira Kalam +11 morewiley +1 more source